[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602004016127D1 - Antagonisten der opioidrezeptoren - Google Patents

Antagonisten der opioidrezeptoren

Info

Publication number
DE602004016127D1
DE602004016127D1 DE602004016127T DE602004016127T DE602004016127D1 DE 602004016127 D1 DE602004016127 D1 DE 602004016127D1 DE 602004016127 T DE602004016127 T DE 602004016127T DE 602004016127 T DE602004016127 T DE 602004016127T DE 602004016127 D1 DE602004016127 D1 DE 602004016127D1
Authority
DE
Germany
Prior art keywords
antagonists
opioid receptors
racemate
diastereomer
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004016127T
Other languages
English (en)
Inventor
Maria Jesus Blanco-Pillado
Dana Rae Benesh
Charles Howard Mitch
Kumiko Tackeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602004016127D1 publication Critical patent/DE602004016127D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58One oxygen atom, e.g. butenolide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004016127T 2003-03-07 2004-03-01 Antagonisten der opioidrezeptoren Expired - Lifetime DE602004016127D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45324303P 2003-03-07 2003-03-07
PCT/US2004/003368 WO2004080996A1 (en) 2003-03-07 2004-03-01 Opioid receptor antagonists

Publications (1)

Publication Number Publication Date
DE602004016127D1 true DE602004016127D1 (de) 2008-10-09

Family

ID=32990743

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004016127T Expired - Lifetime DE602004016127D1 (de) 2003-03-07 2004-03-01 Antagonisten der opioidrezeptoren

Country Status (12)

Country Link
US (1) US7396943B2 (de)
EP (1) EP1606275B1 (de)
JP (1) JP2006519855A (de)
CN (1) CN1753884A (de)
AT (1) ATE406360T1 (de)
AU (1) AU2004220113A1 (de)
BR (1) BRPI0408108A (de)
CA (1) CA2513791A1 (de)
DE (1) DE602004016127D1 (de)
ES (1) ES2312972T3 (de)
MX (1) MXPA05009367A (de)
WO (1) WO2004080996A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
NZ538459A (en) * 2002-09-19 2008-04-30 Lilly Co Eli Diaryl ethers as opioid receptor antagonist
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
US7727985B2 (en) * 2003-04-09 2010-06-01 Millennium Pharmaceuticals, Inc. Beta-carbolines useful for treating inflammatory disease
BRPI0417156A (pt) 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
MXPA06007198A (es) * 2003-12-22 2006-09-04 Lilly Co Eli Antagonistas de receptor opioide.
GB0402137D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
ES2308471T3 (es) 2004-03-12 2008-12-01 Eli Lilly And Company Antagonistas de receptores de opioides.
ES2347577T3 (es) 2004-03-12 2010-11-02 Eli Lilly And Company Antagonistas de receptores opioides.
WO2005092836A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
ATE420858T1 (de) 2004-03-15 2009-01-15 Lilly Co Eli 4-(5-(aminomethyl)-indol-1- ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
WO2006076706A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN104248763A (zh) 2005-03-07 2014-12-31 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
EP1943226A2 (de) 2005-10-13 2008-07-16 Smithkline Beecham Corporation Phenolether als modulatoren der opioidrezeptoren
MX2009002527A (es) * 2006-09-08 2009-03-20 Pfizer Prod Inc Derivados de eter diarilico y usos de los mismos.
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
PE20130480A1 (es) 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
PL2139890T3 (pl) 2007-03-29 2014-11-28 Wyeth Llc Antagoniści obwodowych receptorów opioidowych i ich zastosowania
EP2152671A1 (de) 2007-05-22 2010-02-17 Prosidion Limited Bicyclische aryl- und heteroarylverbindungen zur behandlung von stoffwechselerkrankungen
WO2009030962A1 (en) 2007-09-07 2009-03-12 Prosidion Limited Bicyclic aryl and heteroaryl receptor modulators
JO2797B1 (en) * 2008-01-22 2014-03-15 ايلي ليلي اند كومباني Selective opioid receptor antagonist kappa
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP2012518651A (ja) * 2009-02-23 2012-08-16 マリンクロッド インコーポレイテッド (+)−モルフィナニウムn−オキシドおよびそれらの生成方法
NZ598783A (en) * 2009-09-18 2013-07-26 Adolor Corp Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2012051502A1 (en) * 2010-10-14 2012-04-19 University Of Utah Research Foundation Methods and compositions related to neuroactive thiazoline compounds
CN106117195A (zh) * 2016-06-09 2016-11-16 青岛辰达生物科技有限公司 一种用于治疗白血病的药物达沙替尼的合成方法
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
CN112341404B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 噻唑类衍生物或盐、异构体、其制备方法及用途
US20220370409A1 (en) 2021-05-04 2022-11-24 Janssen Pharmaceuticals, Inc. Compositions And Methods For The Treatment Of Depression
KR20240156409A (ko) 2022-03-07 2024-10-29 얀센 파마슈티칼즈, 인코포레이티드 주요 우울 장애 치료에 사용을 위한 아티카프란트의 다형 형태

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
PT1379239E (pt) 2001-03-29 2007-12-06 Lilly Co Eli N- (2-ariletil)benzilaminas como antagonistas do receptor 5-ht6

Also Published As

Publication number Publication date
JP2006519855A (ja) 2006-08-31
US20060166987A1 (en) 2006-07-27
WO2004080996A1 (en) 2004-09-23
CN1753884A (zh) 2006-03-29
CA2513791A1 (en) 2004-09-23
EP1606275A1 (de) 2005-12-21
BRPI0408108A (pt) 2006-03-01
AU2004220113A1 (en) 2004-09-23
EP1606275B1 (de) 2008-08-27
ES2312972T3 (es) 2009-03-01
MXPA05009367A (es) 2005-11-04
US7396943B2 (en) 2008-07-08
ATE406360T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
ATE406360T1 (de) Antagonisten der opioidrezeptoren
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
DE60302157D1 (de) Opioidrezeptorantagonisten
HRP20050253B1 (hr) Diaril eteri kao opioid antagonisti opioidnih receptora
CO5680444A2 (es) Agonista a-2 no sedante 1-(2,3-dimetil-fenil)-etil-1,3-dihidro-imidazol-2-tiona
TW200714583A (en) Substituted gamma lactams as therapeutic agents
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
ATE545413T1 (de) Antagonisten des opioidrezeptors
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
WO2004000808A3 (en) N-substituted piperidine derivatives as serotonin receptor agents
WO2008005368A3 (en) Piperazines as p2x7 antagonists
BRPI0512516A (pt) composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY
RS51146B (sr) Novi difenil-azetidinon sa poboljšanim fiziološkim osobinama postupak za njegovu proizvodnju,lekovi koji sadrže ovo jedinjenje i njihova upotreba
WO2004082623A3 (en) Substituted piperidine compounds
ATE399770T1 (de) Tachykininrezeptorantagonisten
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
ATE475640T1 (de) Antagonisten des opioidrezeptors
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN